In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Cue Biopharma (CUE – Research Report), with a price target of $7.00. The company’s shares closed yesterday at $3.78.
According to TipRanks, Tenthoff is a 5-star analyst with an average return of 16.0% and a 44.38% success rate. Tenthoff covers the Healthcare sector, focusing on stocks such as Crispr Therapeutics AG, Cue Biopharma, and Moderna.
Currently, the analyst consensus on Cue Biopharma is a Strong Buy with an average price target of $10.00, a 164.55% upside from current levels. In a report released on June 7, JMP Securities also reiterated a Buy rating on the stock with a $15.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
CUE market cap is currently $163.2M and has a P/E ratio of -2.80.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cue Biopharma, Inc. is a biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded on December 31, 2014 and is headquartered in Cambridge, MA.
Read More on CUE:
- Cue Biopharma to Host Investor Call
- Cue Biopharma to Present at the Jefferies 2023 Global Healthcare Conference
- Cue Biopharma Presents Positive Data Update from Ongoing Phase 1 Trials of CUE-101 for Recurrent/Metastatic HPV+ Head and Neck Squamous Cell Carcinoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
- Cue Biopharma Reports First Quarter 2023 Financial Results and Recent Business Highlights
- Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference
